Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24854067 | 0.83 | DRD2 (0.40) | DRD2HTR2CPIK3C3HTR2BHTR2A | |
| SCHEMBL19275749 | 0.82 | CHRNB2 (0.58) | DRD2 | |
| SCHEMBL17358798 | 0.82 | RIPK1 (0.61) | PIK3C3RIPK1 | |
| SCHEMBL17358800 | 0.82 | RIPK1 (0.61) | PIK3C3RIPK1 | |
| SCHEMBL24774827 | 0.82 | PDE2A (0.44) | HTR2C | |
| SCHEMBL24775063 | 0.81 | DRD2 (0.46) | DRD2HTR2CRIPK1DRD3 | |
| SCHEMBL24775482 | 0.79 | RIPK1 (0.44) | PIK3C3RIPK1 | |
| SCHEMBL23449291 | 0.79 | CHRM2 (0.50) | DRD2HTR2CPIK3C3HTR2BCHRM2 | |
| SCHEMBL22473219 | 0.78 | CHRNB2 (0.59) | RIPK1 | |
| SCHEMBL22473392 | 0.78 | CHRNB2 (0.59) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | DRD2 4268/4885HTR2C 3764/4885PIK3C3 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.